NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $1.64 +0.05 (+3.14%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.64 0.00 (0.00%) As of 11/13/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Actinium Pharmaceuticals Stock (NYSE:ATNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ATNM alerts:Sign Up Key Stats Today's Range$1.55▼$1.6450-Day Range$0.97▼$1.6452-Week Range$0.74▼$1.72Volume180,594 shsAverage Volume157,573 shsMarket Capitalization$51.56 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia. Another program, Actimab-A, pairs an antibody targeting CD33 with the alpha-emitting isotope actinium-225 and has been studied for acute myeloid leukemia. These programs are investigational, and the company’s work centers on their clinical development. Actinium Pharmaceuticals is based in the United States.AI Generated. May Contain Errors. Read More Actinium Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreATNM MarketRank™: 2.08688245315 of 5 starsActinium Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 665th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialActinium Pharmaceuticals has a consensus price target of $5.00, representing about 204.9% upside from its current price of $1.64.Amount of Analyst CoverageActinium Pharmaceuticals has received no research coverage in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.04 News SentimentActinium Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.91% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by Institutions27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNM Stock News HeadlinesActinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400 ...November 12 at 10:46 PM | finanznachrichten.deActinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha RadiotherapyNovember 12 at 8:00 AM | prnewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 15 at 1:00 AM | Porter & Company (Ad)Patient enrolment begins in Actinium’s RADIANZ solid tumour trialNovember 12 at 7:44 AM | finance.yahoo.comActinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting RadiotherapyNovember 11, 2026 | prnewswire.comATNM: Introducing ATNM-400's HER3 TargetNovember 9, 2026 | finance.yahoo.comActinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical DevelopmentNovember 9, 2026 | prnewswire.comActinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell DiseaseNovember 4, 2026 | prnewswire.comSee More Headlines ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $1.36 on January 1st, 2026. Since then, ATNM shares have increased by 20.6% and is now trading at $1.64. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) issued its quarterly earnings results on Monday, August, 5th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Plug Power (PLUG), NIO (NIO) and Alibaba Group (BABA). Company Calendar Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATNM's financial health is in the Green zone, according to TradeSmith. ATNM has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ATNM Previous SymbolNYSE:ATNM CIK1388320 Webactiniumpharma.com Phone(646) 677-3870FaxN/AEmployees25Year Founded2000Price Target and Rating Average Price Target for Actinium Pharmaceuticals$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+204.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.82 million Net MarginsN/A Pretax Margin-50,512.35% Return on Equity-100.85% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$35.09 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.25Miscellaneous Outstanding Shares31,441,000Free Float29,324,000Market Cap$51.56 million OptionableOptionable Beta0.27 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:ATNM) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
